Last updated: February 20, 2026
What is the drug associated with NDC 00078-0722?
NDC 00078-0722 refers to Valsartan tablets, primarily marketed as Diovan by Novartis. It is used in the management of hypertension, heart failure, and post-myocardial infarction treatment.
What is the current market landscape?
Market size and demand
- The global antihypertensive drugs market was valued at approximately $29 billion in 2022.
- Valsartan accounts for about 8% of that, translating to roughly $2.3 billion annually.
- The drug has experienced steady demand due to its efficacy and safety profile.
Competitive positioning
- Major competitors include Lisinopril, Amlodipine, and other angiotensin receptor blockers (ARBs).
- The drug faces patent expiry in many markets, leading to increased generic competition.
Key regulations and patent status
- Original patent expired in the U.S. in 2012.
- Generics entered the market post-patent expiration, causing price erosion.
- In some markets, patent disputes or regulatory exclusivities may delay generic entry.
What are historical pricing trends?
Brand-name price points
- In 2012, branded Diovan tablets were approximately $400 per month for a standard dose.
- Average retail price for a 30-day supply (generic) ranged from $10 to $20 depending on dosage and pharmacy discounts.
Generics impact
- Post-patent expiration, generic Valsartan reduced prices to $0.30–$0.50 per pill.
- Largest price reductions occurred within 1–2 years of generic market entry.
Price projection models
Short-term (1–2 years)
- Post-patent expiry, prices stabilize at $0.30–$0.50 per pill.
- Slight price increases possible due to supply chain disruptions or regulatory changes, but overall stable.
Medium-term (3–5 years)
- Further price reductions unlikely unless new formulations or biosimilars enter.
- Market consolidation may lead to slight price increases in certain regions.
Long-term (5+ years)
- Potential re-pricing driven by patent extensions, biosimilar competition, or combination therapies.
- Estimated average price per pill may range from $0.40 to $0.60 in mature markets.
External factors affecting prices
- Regulatory shifts reducing barriers to generic entry.
- Patent litigation outcomes can delay or accelerate price erosion.
- Market penetration of alternative therapies influences demand and pricing.
Future market drivers
- Growing prevalence of hypertension, predicted to reach 1.28 billion adults globally by 2025.
- Increasing adoption of combination therapies that include Valsartan.
- Entry of biosimilars or innovative ARBs may compress prices further.
Investment considerations
- Existing patents and exclusivities are minimal, favoring generic competitiveness.
- Price erosion phase largely completed; future profits depend on volume increases and market access.
- Vertically integrated supply chains could influence pricing strategies.
Summary
| Aspect |
Current Status |
Projection |
| Market size |
~$2.3 billion annually |
Slight growth consistent with hypertension prevalence |
| Price per pill |
$0.30–$0.50 |
Stable; potential slight increase due to supply chain factors |
| Patent situation |
Expired in most jurisdictions |
No new patent protections expected; generic entry continues |
| Competition |
High; multiple generics available |
Remains high; price competition persists |
Key Takeaways
- Post-patent, Valsartan pricing has stabilized at low levels.
- Market demand remains strong owing to hypertension prevalence.
- Price erosion will likely plateau in the short term, with minor fluctuations in the medium and long term.
- Entry of biosimilars or similar drugs may further compress prices in future years.
FAQs
1. What factors most influence Valsartan pricing today?
Price is primarily driven by generic competition, supply chain dynamics, and regulatory policies.
2. Are future price increases possible for Valsartan?
Yes; limited by generic market saturation, patent protections, and competitive pressures. Price increases might occur due to supply constraints or regulatory changes.
3. How does the patent status affect market entry?
Patent expiry in 2012 led to widespread generic entry, lowering prices significantly. No recent patent protections are in place in major markets.
4. What is the estimated price per pill over the next five years?
Between $0.40 and $0.60, barring significant market disruptions or new formulation approvals.
5. How does competition impact profit margins?
Intense generic competition compresses margins; profit growth depends on volume expansion and regional market penetration.
References
[1] IQVIA. (2023). Global Pharmaceutical Market Report.
[2] Novartis. (2022). Diovan Product Details.
[3] EvaluatePharma. (2022). Pharmaceutical Pricing Trends.
[4] World Health Organization. (2023). Global Burden of Hypertension.
[5] U.S. Food and Drug Administration. (2022). ANDA Approvals and Patent Listings.
